Skip to main content
Top
Published in: Calcified Tissue International 6/2012

01-12-2012 | Original Research

Dose-Dependent Short-Term Effects of Single High Doses of Oral Vitamin D3 on Bone Turnover Markers

Authors: Maurizio Rossini, Silvano Adami, Ombretta Viapiana, Elena Fracassi, Luca Idolazzi, Maria Rosaria Povino, Davide Gatti

Published in: Calcified Tissue International | Issue 6/2012

Login to get access

Abstract

We investigated the short-term effects on bone turnover markers of high doses of vitamin D3 in order to identify what initial therapeutic dose can be safely administered in vitamin D-deficient subjects. Thirty-seven elderly subjects [mean age 75 ± 3 (SD) years] were consecutively randomized to the administration of a single oral bolus of 600000, 300000, or 100000 IU vitamin D3. Blood samples were taken at baseline and 1, 3, 7, 14, 30, 60, and 90 days after vitamin D3 administration. Twenty-four subjects served as controls. No relevant changes in bone turnover markers [C-terminal telopeptides of type I collagen (sCTX) and bone-specific alkaline phosphatase (BAP)] were observed in the controls. In treated patients a dose-dependent effect on sCTX was observed. With the administration of 600,000 IU vitamin D3 a significant increase of sCTX was observed already at day 1, and it was sustained for 2 months. The changes in sCTX with smaller doses were considerably lower and reached statistical significance only within the first 3 days with the 300,000 IU dose. BAP remained unchanged in patients given 300,000 and 600,000 IU vitamin D3, while it significantly rose by 15–23 % throughout the observation period in patients given 100,000 IU. Our results indicate that the use of a vitamin D bolus exceeding 100,000 IU may be associated with acute increases of sCTX.
Literature
1.
go back to reference Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373PubMedCrossRef Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373PubMedCrossRef
2.
go back to reference Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501PubMedCrossRef Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501PubMedCrossRef
3.
go back to reference Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRef Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRef
4.
go back to reference Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press, Washington, DC Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press, Washington, DC
5.
go back to reference Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D’Erasmo E, Carnevale V, Scillitani A, Minisola S (2008) Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or vitamin D3 (vitamin D3) in the elderly. J Clin Endocrinol Metab 93:3015–3020PubMedCrossRef Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D’Erasmo E, Carnevale V, Scillitani A, Minisola S (2008) Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or vitamin D3 (vitamin D3) in the elderly. J Clin Endocrinol Metab 93:3015–3020PubMedCrossRef
6.
go back to reference Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR (2009) High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int 20:1407–1415PubMedCrossRef Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR (2009) High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int 20:1407–1415PubMedCrossRef
7.
go back to reference Bischoff-Ferrari HA (2007) How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18:401–407PubMedCrossRef Bischoff-Ferrari HA (2007) How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18:401–407PubMedCrossRef
8.
go back to reference Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (vitamin D3) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469–475PubMedCrossRef Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (vitamin D3) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469–475PubMedCrossRef
9.
go back to reference Heikinheimo R, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105–110PubMedCrossRef Heikinheimo R, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105–110PubMedCrossRef
10.
go back to reference Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA 303:1815–1822PubMedCrossRef Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA 303:1815–1822PubMedCrossRef
11.
go back to reference Rossini M, Gatti D, Viapiana O, Fracassi E, Idolazzi L, Zanoni S, Adami S (2012) Short-term effects on bone turnover markers of a single high dose of oral vitamin D3. J Clin Endocrinol Metab 97:E622–E626PubMedCrossRef Rossini M, Gatti D, Viapiana O, Fracassi E, Idolazzi L, Zanoni S, Adami S (2012) Short-term effects on bone turnover markers of a single high dose of oral vitamin D3. J Clin Endocrinol Metab 97:E622–E626PubMedCrossRef
12.
go back to reference Wu F, Staykova T, Horne A, Horne A, Clearwater J, Ames R, Mason B, Orr-Walker B, Gamble G, Scott M, Reid I (2003) Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. N Z Med J 116:U536PubMed Wu F, Staykova T, Horne A, Horne A, Clearwater J, Ames R, Mason B, Orr-Walker B, Gamble G, Scott M, Reid I (2003) Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. N Z Med J 116:U536PubMed
13.
go back to reference Hekkarinen T, Valimaki VV, Aaarum S, Turpeinen U, Hamalainen E, Loyttyniemi E, Valimaki MJ (2010) The same annual dose of 292000 IU of vitamin D3 (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D3 concentrations and renal function. Clin Endocrinol 72:455–461CrossRef Hekkarinen T, Valimaki VV, Aaarum S, Turpeinen U, Hamalainen E, Loyttyniemi E, Valimaki MJ (2010) The same annual dose of 292000 IU of vitamin D3 (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D3 concentrations and renal function. Clin Endocrinol 72:455–461CrossRef
14.
go back to reference Giusti A, Barone A, Pioli G, Girasole G, Razzamo M, Pizzonia M, Pedrazzoni M, Palummeri E, Bianchi G (2010) Heterogeneity in serum 25-hydroxy-vitamin D response to vitamin D3 in elderly women with secondary hyperparathyroidism and vitamin D deficiency. J Am Geriatr Soc 58:1489–1495PubMedCrossRef Giusti A, Barone A, Pioli G, Girasole G, Razzamo M, Pizzonia M, Pedrazzoni M, Palummeri E, Bianchi G (2010) Heterogeneity in serum 25-hydroxy-vitamin D response to vitamin D3 in elderly women with secondary hyperparathyroidism and vitamin D deficiency. J Am Geriatr Soc 58:1489–1495PubMedCrossRef
15.
go back to reference Plum LA, DeLuca HF (2009) The functional metabolism and molecular biology of vitamin D action. Clin Rev Bone Miner Metab 7:20–41CrossRef Plum LA, DeLuca HF (2009) The functional metabolism and molecular biology of vitamin D action. Clin Rev Bone Miner Metab 7:20–41CrossRef
16.
go back to reference Aubin JE, Bonnelye E (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11:905–913PubMedCrossRef Aubin JE, Bonnelye E (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11:905–913PubMedCrossRef
17.
go back to reference Demay MB, Gerardi JM, DeLuca HF, Kronenberg HM (1990) DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsiveness to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 87:369–373PubMedCrossRef Demay MB, Gerardi JM, DeLuca HF, Kronenberg HM (1990) DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsiveness to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 87:369–373PubMedCrossRef
Metadata
Title
Dose-Dependent Short-Term Effects of Single High Doses of Oral Vitamin D3 on Bone Turnover Markers
Authors
Maurizio Rossini
Silvano Adami
Ombretta Viapiana
Elena Fracassi
Luca Idolazzi
Maria Rosaria Povino
Davide Gatti
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2012
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-012-9637-y

Other articles of this Issue 6/2012

Calcified Tissue International 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.